James Noble
Chairman of the Board of Directors
Chairman of the Board of Directors since 2020.
M.A. from the University of Oxford.
Other appointments:
Chairman of the Board of Pneumagen Ltd, Ingenox Therapeutics, and another private UK-based cancer research company. Board member of Lava Therapeutics.
Previous experience:
Co-founder and CEO of Adaptimmune and Immunocore. Board member and Deputy Chairman of GW Pharmaceuticals until its acquisition by Jazz Pharmaceuticals. Chairman and CEO of Avidex, which was acquired by Medigene. Other positions as Board member include companies, such as Medigene, PowderJect Pharmaceuticals and CuraGen Corporation.
Holds 51,450 shares, and bonds of a nominal value of SEK 2,500,000.1
Independent in relation to Orexo, its management and the company’s largest shareholders.
Staffan Lindstrand
Board member
Board member since 2002.
M.Sc. in Engineering.
Other appointments:
Partner of HealthCap since 1997, Board member of HealthCap AB, Doctrin AB, Elsa Science AB, GET.ON Institut für Online Gesundheitstrainings GmbH, and The Swedish Association of Exchange-listed companies.
Previous experience:
Ten years in investment banking.
Holds 30,843 shares.1
Independent in relation to Orexo, its management and the company’s largest shareholders.
Robin Evers
Board member
Board member since 2023.
Management Studies at University of Reading and a BSc. in Molecular Biology from University of Portmouth.
Other appointments:
Senior Vice President, Head of Global Regulatory Affairs & Global Safety, Medical Writing and R&D Quality, at Novo Nordisk A/S.
Previous experience:
Prior to his current position, similar senior leading position at Novo Nordisk since 2013. Vice President, Worldwide Safety & Regulatory at Pfizer Inc. and Vice President and Head of Global Regulatory Affairs for Europe, Middle East & Africa at Wyeth Pharmaceuticals. Combined, more than 25 years in the pharmaceutical industry with expertise in the development of biologics, vaccines, and small molecule drugs.
Does not hold any shares in Orexo.1
Independent in relation to Orexo and its management, but dependent in relation to the company’s largest shareholders.
Charlotte Hansson
Board member
Board member since 2020.
MSc. in Business Administration from the School of Business, Economics and Law at the University of Gothenburg.
Other appointments:
CFO at Tele 2 AB.
Previous experience:
CFO at Systembolaget AB, CFO & Executive VP at Cision AB, CFO at Addici AB and various positions within business controlling at Modern Times Group.
Holds 8,500 shares.1
Independent in relation to Orexo, its management and the company’s largest shareholders.
Christine Rankin
Board member
Board member since 2022.
BSc. in Business Administration and Economics from Stockholm University.
Other appointments:
Board member of CoinShares International Ltd, Bonesupport AB and 4C Group AB.
Previous experience:
Board member of Adventure Box Technology AB and Technopolis Plc. SVP Corporate Control at Veoneer Inc, CFO at Cherry AB, interim CFO/Head of Finance at Serneke Group, Head of Corporate Control at Spotify and Partner/Head of the US Capital Markets group in Sweden at PwC.
Holds 5,595 shares.1
Independent in relation to Orexo, its management and the company’s largest shareholders.
Michael J Matly
Board member
Board member since 2022.
MBA from Harvard Business School, Medical Doctorate from Mayo Clinic College of Medicine, and BSc. from Cornell University.
Other appointments:
Co-Founder and Managing Director at 111° West Capital.
Previous experience:
Managing Director at Montreux Growth Partners and Director within Business Development and Investments at Mayo Clinic.
Holds 5,870 shares.1
Independent in relation to Orexo, its management and the company’s largest shareholders.
Mary Pat Christie
Board member
Board member since 2019.
MBA.
Other appointments:
Board member of Hackensack Meridian Health’s Carrier Clinic and Restaurant Technologies.
Previous experience:
Managing Director at Angelo Gordon & Co., where she focused on business development of new fund strategies and new strategic alliances. Prior to that at Cantor Fitzgerald as an Institutional Salesperson and was an original partner at the Seaport Group. Christie was also the founder of Mend- ham Capital Management. Her career also includes high level roles at JP Morgan, Donaldson, Lufkin & Jenrette, and Fleet Bank.
Holds 7,015 shares.1
Independent in relation to Orexo, its management and the company’s largest shareholders.
Fred Wilkinson
Board member
Board member since 2019
MBA., B.Sc. Pharmacy
Other appointments:
Board member of Alter Pharma Group.
Previous experience:
Chief Executive Officer and Board member of Impax Laboratories, Inc., President of the Specialty business at Watson Pharmaceuticals, Inc. (currently Allergan), President of Duramed Pharmaceuticals, Inc., Chief Executive Officer of Columbia Laboratories, and multiple positions at Sandoz Pharmaceutical Corporation, Inc.
Holds 10,200 shares.1
Independent in relation to Orexo, its management and the company’s largest shareholders.
1 As of December 31, 2023
Nikolaj Sørensen
President and CEO
President and CEO since 2013, employed since 2011.
BSc., and MSc., Copenhagen Business School, Denmark.
Other appointments:
Member of the Board of Moberg Pharma AB and Gesynta Pharma AB.
Previous experience:
Senior management positions at Pfizer Inc. with a focus on commercialization in Europe. Chairman of the Board and Managing Director at Pfizer AB. Prior to Pfizer, management consultant at Boston Consulting Group (BCG), leading several projects within M&A, commercial transformation, and turn-arounds.
Holds 156,135 shares and stock options/share awards entitling to 517,429 shares.1
Fredrik Järrsten
EVP and Chief Financial Officer
EVP and Chief Financial Officer since 2022
BSc. and MSc. majoring in Accounting and Finance at the Stockholm School of Economics, Sweden, and International Business at the University of Michigan – Stephen M. Ross School of Business, US.
Previous experience:
CFO at Vivesto AB, 2021-June 2022. CFO and deputy CEO at Karolinska Development AB, 2018-2020. CFO at Bactiguard AB, 2014-2017. Prior to holding various positions as CFO Fredrik Järrsten served as Director Business Development at Aleris AB, 2006-2013. Additionally Fredrik Järrsten has worked as Investment Manager at Litorina Kapital and within Corporate Finance at Lazard and SEB Enskilda.
Holds 23,190 shares and stock options/share awards entitling to 218,966 shares.1
Robert A. DeLuca
President Orexo US Inc.
President of Orexo US Inc. since 2013
R.Ph.
Other appointments:
Member of the American Society of Addiction Medicine, Academy of Managed Care Pharmacy and the American and New Jersey Pharmacists Associations. Co-chair, SDHB PheoPara Coalition.
Previous experience:
Extensive experience establishing commercial operations in the US with a combined background in market access, marketing, and sales. Has held leadership positions at multinational pharmaceutical companies including Sanofi-Aventis, Schering Plough, Berlex and Pharmacia, and most recently served as Chief Commercial Officer at Archimedes Pharmaceuticals.
Holds 9,396 shares and stock options/share awards entitling to 268,988 shares.1
Edward Kim
Chief Medical Officer
Chief Medical Officer since 2022
MBA in Healthcare Management from University of Massachusetts, US, MD from Thomas Jefferson University, US and AB in Biology from Harvard University, US.
Previous experience:
Extensive experience in medical affairs, health economics and outcomes research, and clinical development across multiple senior positions within the pharmaceutical industry. Most recently served as VP and Head of Medical Affairs at Biohaven Pharmaceuticals. Over a decade of experience in clinical practice, academia, and hospital administration as a board-certified psychiatrist.
Does not hold any shares in Orexo. Owns stock options/share awards entitling to 65,600 shares.1
Robert Rönn
SVP and Head of R&D
SVP and Head of R&D since 2019, employed since 2007.
MSc. in Chemical Engineering and PhD. in Medicinal Chemistry, Uppsala University, Sweden.
Previous experience:
Head of Pharmaceutical Development & IP at Orexo AB since 2016 and prior to that extensive experience of drug discovery and development, as well as patent prosecution and litigation, from various key positions at Biolipox AB and Orexo AB.
Holds 16,544 shares and stock options/share awards entitling to 208,735 shares.1
Cecilia Coupland
SVP and Head of Operations
SVP and Head of Operations since 2019, employed since 2006.
MSc in Chemical Engineering, Uppsala University, Sweden.
Previous experience:
Head of Supply Chain & Planning at Orexo since 2014 and prior to that extensive experience of global pharmaceutical manufacturing and supply chain management, as well as drug development and project management, from various key positions at AstraZeneca and Orexo AB.
Holds 14,390 shares stock options/share awards entitling to 192,523 shares.1
1 As of December 31, 2023
Note: Alloted long-term incentive programs with vesting terms in accordance with approval from Annual General Meeting.